{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:52:38Z","timestamp":1777665158896,"version":"3.51.4"},"reference-count":175,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.vaccine.2012.11.068","type":"journal-article","created":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T04:16:43Z","timestamp":1354853803000},"page":"735-749","source":"Crossref","is-referenced-by-count":62,"title":["Micro\/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends"],"prefix":"10.1016","volume":"31","author":[{"given":"Ali","family":"Badiee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Heravi Shargh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Khamesipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2012.11.068_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0010","article-title":"Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials","volume":"57","author":"Khatami","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0015","first-page":"423","article-title":"Leishmaniasis vaccine candidates for development: a global overview","volume":"123","author":"Khamesipour","year":"2006","journal-title":"Indian J Med Res"},{"issue":"December (Suppl. 1)","key":"10.1016\/j.vaccine.2012.11.068_bib0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/00034983.1995.11813017","article-title":"Vaccines against leishmaniasis","volume":"89","author":"Modabber","year":"1995","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2012.00069","article-title":"Vaccines for canine leishmaniasis","volume":"3","author":"Palatnik-de-Sousa","year":"2012","journal-title":"Front Immunol"},{"issue":"December (52)","key":"10.1016\/j.vaccine.2012.11.068_bib0030","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","article-title":"First generation leishmaniasis vaccines: a review of field efficacy trials","volume":"26","author":"Noazin","year":"2008","journal-title":"Vaccine"},{"issue":"May (28)","key":"10.1016\/j.vaccine.2012.11.068_bib0035","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1016\/j.vaccine.2005.02.015","article-title":"Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis","volume":"23","author":"Khamesipour","year":"2005","journal-title":"Vaccine"},{"issue":"November (Suppl. 1)","key":"10.1016\/j.vaccine.2012.11.068_bib0040","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.ijantimicag.2010.06.024","article-title":"Leishmaniasis vaccines: past, present and future","volume":"36","author":"Modabber","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.vaccine.2012.11.068_bib0045","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1371\/journal.pntd.0000943","article-title":"Vaccines for the leishmaniases: proposals for a research agenda","volume":"5","author":"Costa","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2012.11.068_bib0050","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1016\/j.vaccine.2009.05.084","article-title":"Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis \u2013 a meta-analysis","volume":"27","author":"Noazin","year":"2009","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0055","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second-generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol"},{"issue":"January (5144)","key":"10.1016\/j.vaccine.2012.11.068_bib0060","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect of interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Science"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2012.11.068_bib0065","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.163.8.4481","article-title":"Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis","volume":"163","author":"Kenney","year":"1999","journal-title":"J Immunol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2012.11.068_bib0070","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/IAI.69.6.4103-4108.2001","article-title":"Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease","volume":"69","author":"Campos-Neto","year":"2001","journal-title":"Infect Immun"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","article-title":"Leishmaniasis: current status of vaccine development","volume":"14","author":"Handman","year":"2001","journal-title":"Clin Microbiol Rev"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4161\/hv.5.5.7607","article-title":"Vaccines and vaccination strategies against human cutaneous leishmaniasis","volume":"5","author":"Okwor","year":"2009","journal-title":"Hum Vaccin"},{"issue":"August\u2013September (2\/3)","key":"10.1016\/j.vaccine.2012.11.068_bib0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-3083.2007.01964.x","article-title":"Role of sand fly saliva in human and experimental leishmaniasis: current insights","volume":"66","author":"Andrade","year":"2007","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.11.068_bib0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1674-8301(10)60004-8","article-title":"A review of adjuvants for Leishmania vaccine candidates","volume":"24","author":"Mutiso","year":"2010","journal-title":"J Biomed Res"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.smim.2010.04.007","article-title":"Adjuvants for cancer vaccines","volume":"22","author":"Dubensky","year":"2010","journal-title":"Semin Immunol"},{"issue":"19","key":"10.1016\/j.vaccine.2012.11.068_bib0100","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1016\/j.vaccine.2007.01.111","article-title":"Vaccine adjuvants revisited","volume":"25","author":"Aguilar","year":"2007","journal-title":"Vaccine"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2012.11.068_bib0105","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1517\/17425240903018863","article-title":"Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators","volume":"6","author":"Nordly","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"March (14)","key":"10.1016\/j.vaccine.2012.11.068_bib0110","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2008.01.023","article-title":"Vaccines for leishmaniasis in the fore coming 25 years","volume":"26","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","article-title":"New horizons in adjuvants for vaccine development","volume":"30","author":"Reed","year":"2009","journal-title":"Trends Immunol"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2012.11.068_bib0120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/17425247.5.7.789","article-title":"Recent developments in leishmaniasis vaccine delivery systems","volume":"5","author":"Bhowmick","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11908-009-0080-9","article-title":"NLR agonists, and other immune modulators as infectious disease vaccine adjuvants","volume":"12","author":"Higgins","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0130","series-title":"Leishmania","first-page":"169","article-title":"Anti-leishmania vaccine","author":"Campos-Neto","year":"2002"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2012.11.068_bib0135","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/4000","article-title":"Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection","volume":"4","author":"Gurunathan","year":"1998","journal-title":"Nat Med"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2012.11.068_bib0140","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1440-1711.2004.01288.x","article-title":"Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines","volume":"82","author":"Vajdy","year":"2004","journal-title":"Immunol Cell Biol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0145","first-page":"59","article-title":"Chitosan-based delivery systems for protein therapeutics and antigens","volume":"62","author":"Amidi","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0150","first-page":"465","article-title":"Targeting cells for drug and gene delivery: emerging applications of mannans and mannan binding lectins","volume":"68","author":"Gupta","year":"2009","journal-title":"J Sci Ind Res"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0155","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2174\/187152308786847816","article-title":"Biodegradable polymer based particulate carrier(s) for the delivery of proteins and peptides","volume":"7","author":"Mishra","year":"2008","journal-title":"Anti-Inflamm Anti-Allergy Agents Med Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2012.11.068_bib0160","first-page":"14","article-title":"Polymeric delivery systems in biotechnology: a mini review","volume":"21","author":"Narayani","year":"2007","journal-title":"Trends Biomater Artif Organs"},{"issue":"1","key":"10.1016\/j.vaccine.2012.11.068_bib0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mib.2009.12.001","article-title":"Polymeric particles in vaccine delivery","volume":"13","author":"Rice-Ficht","year":"2010","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0170","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3390\/ma3031928","article-title":"Targeted delivery of protein drugs by nanocarriers","volume":"3","author":"Solaro","year":"2010","journal-title":"Materials"},{"issue":"December (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijpharm.2008.06.030","article-title":"Immunomodulatory biomaterials","volume":"364","author":"Mallapragada","year":"2008","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.vaccine.2012.11.068_bib0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/erv.09.160","article-title":"Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists","volume":"9","author":"Black","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"September\u2013October (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0185","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1021\/bm0503221","article-title":"Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigen-presenting cells","volume":"6","author":"Jain","year":"2005","journal-title":"Biomacromolecules"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2012.11.068_bib0190","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.4049\/jimmunol.158.6.2723","article-title":"Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules","volume":"158","author":"Shen","year":"1997","journal-title":"J Immunol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0195","first-page":"183","article-title":"Adjuvants and delivery systems in veterinary vaccinology: current state and future developments","volume":"156","author":"Heegaard","year":"2010","journal-title":"Arch Virol"},{"issue":"October (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0200","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1586\/14760584.6.5.797","article-title":"Nanoparticles and microparticles as vaccine-delivery systems","volume":"6","author":"Singh","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0205","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/14760584.2.2.269","article-title":"Microparticles as vaccine adjuvants and delivery systems","volume":"2","author":"O\u2018Hagan","year":"2003","journal-title":"Expert Rev Vaccines"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0210","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2567.2006.02506.x","article-title":"Mannan-mediated gene delivery for cancer immunotherapy","volume":"120","author":"Tang","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0215","series-title":"Delivery systems for the treatment and prevention of leishmaniasis, vol. 79","first-page":"134","author":"Espuelas","year":"2009"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.11.068_bib0220","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"October (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0225","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/mthe.2000.0142","article-title":"Development of biomaterials for gene therapy","volume":"2","author":"Han","year":"2000","journal-title":"Mol Ther"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0230","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/14712590902849224","article-title":"Delivery strategies to enhance mucosal vaccination","volume":"9","author":"Chadwick","year":"2009","journal-title":"Expert Opin Biol Ther"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0235","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/17425247.2011.558081","article-title":"Liposomal vaccine delivery systems","volume":"8","author":"Henriksen-Lacey","year":"2011","journal-title":"Expert Opin Drug Deliv"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2012.11.068_bib0240","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1586\/erv.10.89","article-title":"Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses","volume":"9","author":"Oyewumi","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"December (35)","key":"10.1016\/j.vaccine.2012.11.068_bib0245","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1016\/j.biomaterials.2007.08.015","article-title":"Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response","volume":"28","author":"Kanchan","year":"2007","journal-title":"Biomaterials"},{"issue":"June (27)","key":"10.1016\/j.vaccine.2012.11.068_bib0250","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1016\/j.vaccine.2009.03.040","article-title":"Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1\/Th2 bias in the immune response and protection against infection","volume":"27","author":"Mann","year":"2009","journal-title":"Vaccine"},{"issue":"November (1\/2)","key":"10.1016\/j.vaccine.2012.11.068_bib0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0264-410X(02)00435-8","article-title":"Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres","volume":"21","author":"Gutierro","year":"2002","journal-title":"Vaccine"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","article-title":"Pathogen recognition and development of particulate vaccines: does size matter?","volume":"40","author":"Xiang","year":"2006","journal-title":"Methods"},{"issue":"December (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0265","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbamcr.2005.06.009","article-title":"Secrets of caveolae- and lipid raft-mediated endocytosis revealed by mammalian viruses","volume":"1746","author":"Pelkmans","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0270","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur J Immunol"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0275","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","article-title":"Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model","volume":"298","author":"Foged","year":"2005","journal-title":"Int J Pharm"},{"issue":"October (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/erv.11.166","article-title":"Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems","volume":"11","author":"Doroud","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"September (1\/2)","key":"10.1016\/j.vaccine.2012.11.068_bib0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0168-3659(01)00412-6","article-title":"Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?","volume":"76","author":"Thiele","year":"2001","journal-title":"J Control Release"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2012.11.068_bib0290","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1073\/pnas.0600997103","article-title":"Role of target geometry in phagocytosis","volume":"103","author":"Champion","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.vaccine.2012.11.068_bib0295","first-page":"208","article-title":"Synthetic particulate antigen delivery systems for vaccination","volume":"24","author":"Espuelas","year":"2005","journal-title":"Inmunologia"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0300","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ymthe.2004.12.006","article-title":"Formation and intracellular trafficking of lipoplexes and polyplexes","volume":"11","author":"Elouahabi","year":"2005","journal-title":"Mol Ther"},{"issue":"May (15)","key":"10.1016\/j.vaccine.2012.11.068_bib0305","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.addr.2012.05.009","article-title":"Cationic lipids activate intracellular signaling pathways","volume":"64","author":"Lonez","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0310","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11095-006-9180-5","article-title":"Lipid-based nanoparticles for nucleic acid delivery","volume":"24","author":"Li","year":"2007","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0315","series-title":"Multifunctional Pharmaceutical Nanocarriers","article-title":"Charge modification of pharmaceytical nanocarriers: biological implications","author":"Nafee","year":"2008"},{"issue":"January\u2013March (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0320","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/02652049009028426","article-title":"Targeted delivery of low dose doxorubicin hydrochloride administered via magnetic albumin microspheres in rats","volume":"7","author":"Gupta","year":"1990","journal-title":"J Microencapsul"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0325","series-title":"Vaccine adjuvants: preparation methods and research protocols","article-title":"Compounds as vaccine adjuvants","author":"Gupta","year":"2000"},{"issue":"May\u2013June (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0330","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0035-9203(03)90171-4","article-title":"Alum-precipitated autoclaved Leishmania major plus bacille Calmette\u2013Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers","volume":"97","author":"Kamil","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"December (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0335","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1179\/146532806X152890","article-title":"Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major+BCG) in children: an extended phase II study","volume":"26","author":"Khalil","year":"2006","journal-title":"Ann Trop Paediatr"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-9292-6-7","article-title":"Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis","volume":"6","author":"Ghalib","year":"2007","journal-title":"Kinetoplastid Biol Dis"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2012.11.068_bib0345","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.intimp.2011.05.008","article-title":"Vaccine candidates for leishmaniasis: a review","volume":"11","author":"Nagill","year":"2011","journal-title":"Int Immunopharmacol"},{"issue":"33","key":"10.1016\/j.vaccine.2012.11.068_bib0350","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1016\/j.vaccine.2009.05.043","article-title":"Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants","volume":"27","author":"Poot","year":"2009","journal-title":"Vaccine"},{"issue":"June (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0355","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00436-008-0921-8","article-title":"Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis","volume":"103","author":"Keshavarz Valian","year":"2008","journal-title":"Parasitol Res"},{"issue":"April (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0360","first-page":"89","article-title":"Immune response of BALB\/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae","volume":"27","author":"Nateghi Rostami","year":"2010","journal-title":"Trop Biomed"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0365","series-title":"Drug delivery systems, vol. 32","first-page":"54","author":"Kshirsagar","year":"2000"},{"issue":"2","key":"10.1016\/j.vaccine.2012.11.068_bib0370","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0169-409X(99)00064-2","article-title":"Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells","volume":"41","author":"Rao","year":"2000","journal-title":"Adv Drug Deliv Rev"},{"issue":"13","key":"10.1016\/j.vaccine.2012.11.068_bib0375","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.vaccine.2012.01.070","article-title":"Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens","volume":"30","author":"Watson","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0380","series-title":"Scholarly Research Exchange 2009","article-title":"Searching genes encoding leishmania antigens for diagnosis and protection","author":"Soto","year":"2009"},{"issue":"July (29\/30)","key":"10.1016\/j.vaccine.2012.11.068_bib0385","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1016\/j.vaccine.2006.04.062","article-title":"Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB\/c mice","volume":"24","author":"Jaafari","year":"2006","journal-title":"Vaccine"},{"issue":"August (32)","key":"10.1016\/j.vaccine.2012.11.068_bib0390","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1016\/j.vaccine.2007.05.009","article-title":"The role of CpG ODN in enhancement of immune response and protection in BALB\/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome","volume":"25","author":"Jaafari","year":"2007","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0395","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/CVI.00413-07","article-title":"Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB\/c mice","volume":"15","author":"Badiee","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0400","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exppara.2006.07.002","article-title":"Leishmania major: immune response in BALB\/c mice immunized with stress-inducible protein 1 encapsulated in liposomes","volume":"115","author":"Badiee","year":"2007","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0405","first-page":"98","article-title":"Evaluation of immune response against leishmaniasis in resistance C57 BL\/6 mice immunized with liposomes containing autoclaved Leishmania major with BCG","volume":"10","author":"Sohrabi","year":"2005","journal-title":"Cell Mol Biol Lett"},{"issue":"April (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0410","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00232-006-0005-6","article-title":"Mimetic membrane system to carry multiple antigenic proteins from Leishmania amazonensis","volume":"210","author":"Santos","year":"2006","journal-title":"J Membr Biol"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0415","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J Control Release"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0420","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-3024.2007.00937.x","article-title":"Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB\/c mice through uptake by peritoneal macrophages","volume":"29","author":"Shimizu","year":"2007","journal-title":"Parasite Immunol"},{"issue":"May (15\/16)","key":"10.1016\/j.vaccine.2012.11.068_bib0425","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.vaccine.2003.11.008","article-title":"Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition","volume":"22","author":"Foged","year":"2004","journal-title":"Vaccine"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2012.11.068_bib0430","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/1521-4141(200006)30:6<1740::AID-IMMU1740>3.0.CO;2-U","article-title":"Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway","volume":"30","author":"Nakanishi","year":"2000","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2012.11.068_bib0435","doi-asserted-by":"crossref","first-page":"e1429","DOI":"10.1371\/journal.pntd.0001429","article-title":"Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection","volume":"5","author":"Mazumder","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0440","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2009.09.018","article-title":"Comparison of liposome based antigen delivery systems for protection against Leishmania donovani","volume":"141","author":"Bhowmick","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0445","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2180-10-181","article-title":"Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis","volume":"10","author":"Ravindran","year":"2010","journal-title":"BMC Microbiol"},{"issue":"26","key":"10.1016\/j.vaccine.2012.11.068_bib0450","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/j.vaccine.2012.03.040","article-title":"Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis","volume":"30","author":"Heravi Shargh","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2012.11.068_bib0455","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00436-011-2806-5","article-title":"Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis","volume":"111","author":"Heravi Shargh","year":"2012","journal-title":"Parasitol Res"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0460","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/mp2002494","article-title":"Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route","volume":"9","author":"Ravindran","year":"2012","journal-title":"Mol Pharm"},{"issue":"November (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0465","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.colsurfb.2009.06.025","article-title":"Enhancement of immune response and protection in BALB\/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition","volume":"74","author":"Badiee","year":"2009","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0470","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.exppara.2008.12.015","article-title":"The role of liposome charge on immune response generated in BALB\/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63)","volume":"121","author":"Badiee","year":"2009","journal-title":"Exp Parasitol"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0475","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1128\/IAI.01739-07","article-title":"Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection","volume":"77","author":"Bhowmick","year":"2009","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2012.11.068_bib0480","first-page":"47","article-title":"The role of liposomal CpG ODN on the course of L. major infection in BALB\/C mice","volume":"5","author":"Hejazi","year":"2010","journal-title":"Iranian J Parasitol"},{"issue":"November (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0485","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.exppara.2012.06.014","article-title":"The role of liposome\u2013protamine\u2013DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by Leishmania major in BALB\/c mice","volume":"132","author":"Alavizadeh","year":"2012","journal-title":"Exp Parasitol"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0490","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1645\/GE-356R1","article-title":"Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens","volume":"91","author":"Mazumdar","year":"2005","journal-title":"J Parasitol"},{"issue":"August (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0495","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0378-5173(99)00122-2","article-title":"Proniosomes: a novel drug carrier preparation","volume":"185","author":"Hu","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0500","series-title":"Vaccination of C57BL\/10 Mice against Cutaneous Leishmaniasis. Use of purified gp63 encapsulated into niosomes surfactants vesicles: a novel approach","author":"LezamaD\u00e1vila","year":"1999"},{"issue":"December (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0505","first-page":"219","article-title":"Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study","volume":"29","author":"Pardakhty","year":"2011","journal-title":"J Microencapsul"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0510","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/meth.1999.0832","article-title":"Squalene and squalane emulsions as adjuvants","volume":"19","author":"Allison","year":"1999","journal-title":"Methods"},{"issue":"May (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0515","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/10611860801900082","article-title":"Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice","volume":"16","author":"Shahiwala","year":"2008","journal-title":"J Drug Target"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0520","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.vaccine.2011.11.005","article-title":"The development and clinical evaluation of second-generation leishmaniasis vaccines","volume":"30","author":"Duthie","year":"2012","journal-title":"Vaccine"},{"issue":"November (45)","key":"10.1016\/j.vaccine.2012.11.068_bib0525","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni","year":"2005","journal-title":"Vaccine"},{"issue":"October (42)","key":"10.1016\/j.vaccine.2012.11.068_bib0530","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1016\/j.vaccine.2007.08.001","article-title":"Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant","volume":"25","author":"Goto","year":"2007","journal-title":"Vaccine"},{"issue":"May (21)","key":"10.1016\/j.vaccine.2012.11.068_bib0535","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.vaccine.2009.02.079","article-title":"Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection","volume":"27","author":"Goto","year":"2009","journal-title":"Vaccine"},{"issue":"March (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0540","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cimid.2009.12.003","article-title":"Comparison between three adjuvants for a vaccine against canine leishmaniasis: in vitro evaluation of macrophage killing ability","volume":"33","author":"Trotta","year":"2010","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2012.11.068_bib0545","first-page":"107","article-title":"Montanide ISA 720 is more effective than BCG as an adjuvant for Leishmania killed vaccine in BALB\/c mice","volume":"7","author":"Mutiso","year":"2009","journal-title":"Int J Integr Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.11.068_bib0550","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1674-8301(12)60002-5","article-title":"Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops)","volume":"26","author":"Mutiso","year":"2012","journal-title":"J Biomed Res"},{"issue":"September (1)\u2013(2)","key":"10.1016\/j.vaccine.2012.11.068_bib0555","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0304-4017(01)00486-1","article-title":"An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine","volume":"100","author":"Gradoni","year":"2001","journal-title":"Vet Parasitol"},{"issue":"April (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0560","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1365-2249.2000.01160.x","article-title":"Vaccination of BALB\/c mice with Leishmania major amastigote-specific cysteine proteinase","volume":"120","author":"Rafati","year":"2000","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2012.11.068_bib0565","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.3390\/ijms11093298","article-title":"Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects","volume":"11","author":"Mansour","year":"2010","journal-title":"Int J Mol Sci"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0570","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/14760584.3.4.453","article-title":"Antigen delivery systems","volume":"3","author":"Kersten","year":"2004","journal-title":"Expert Rev Vaccines"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0575","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1166\/jnn.2008.274","article-title":"New aspects of nanopharmaceutical delivery systems","volume":"8","author":"Marcato","year":"2008","journal-title":"J Nanosci Nanotechnol"},{"issue":"May (8)","key":"10.1016\/j.vaccine.2012.11.068_bib0580","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.addr.2007.05.017","article-title":"Nanotechnology in vaccine delivery","volume":"60","author":"Peek","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"December (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0585","first-page":"639","article-title":"Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins","volume":"27","author":"Tafaghodi","year":"2010","journal-title":"Trop Biomed"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0590","first-page":"1265","article-title":"Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN","volume":"108","author":"Tafaghodi","year":"2010","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0595","first-page":"835","article-title":"Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB\/c mice","volume":"6","author":"Danesh-Bahreini","year":"2011","journal-title":"Int J Nanomed"},{"issue":"September\u2013December (5\/6)","key":"10.1016\/j.vaccine.2012.11.068_bib0600","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1051\/vetres:2005033","article-title":"Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis","volume":"36","author":"Fujiwara","year":"2005","journal-title":"Vet Res"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0605","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/0974-777X.62881","article-title":"Leishmaniasis vaccine: where are we today?","volume":"2","author":"Kedzierski","year":"2010","journal-title":"J Glob Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2012.11.068_bib0610","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0192-0561(89)90159-8","article-title":"Protective effect of L. donovani antigens using glucan as an adjuvant","volume":"11","author":"Obaid","year":"1989","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0615","series-title":"Hyperbranched polymers. Encyclopedia of polymer science and technology","author":"Hult","year":"2002"},{"issue":"1","key":"10.1016\/j.vaccine.2012.11.068_bib0620","first-page":"80","article-title":"Solid lipid nanoparticles: a review","volume":"2","author":"Ekambaram","year":"2012","journal-title":"Sci Revs Chem Commun"},{"issue":"3","key":"10.1016\/j.vaccine.2012.11.068_bib0625","doi-asserted-by":"crossref","first-page":"320","DOI":"10.18433\/J3R30T","article-title":"Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations","volume":"13","author":"Doroud","year":"2010","journal-title":"J Pharm Pharm Sci"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2012.11.068_bib0630","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-3024.2011.01289.x","article-title":"Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against L. major infection in C57BL\/6 mice","volume":"33","author":"Doroud","year":"2011","journal-title":"Parasite Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.11.068_bib0880","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2011.04.011","article-title":"Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection","volume":"153","author":"Doroud","year":"2011","journal-title":"J Control Release"},{"issue":"August (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0640","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejps.2004.05.005","article-title":"Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity","volume":"22","author":"Homhuan","year":"2004","journal-title":"Eur J Pharm Sci"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0645","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/14760584.2.2.189","article-title":"Virosomal adjuvanted antigen delivery systems","volume":"2","author":"Moser","year":"2003","journal-title":"Expert Rev Vaccines"},{"issue":"April (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0650","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1021\/cb600086b","article-title":"Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate","volume":"1","author":"Liu","year":"2006","journal-title":"ACS Chem Biol"},{"issue":"July (33)","key":"10.1016\/j.vaccine.2012.11.068_bib0655","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1016\/j.vaccine.2009.05.032","article-title":"ISCOMs and ISCOMATRIX","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2012.11.068_bib0660","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1016\/j.vaccine.2008.06.024","article-title":"In vivo activity of cationic immune stimulating complexes (PLUSCOMs)","volume":"26","author":"McBurney","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0665","series-title":"In-vivo delivery of DNA vaccines using metallo-lipid nanoparticles","author":"Gomez","year":"2008"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0670","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-10-3","article-title":"Improvement of different vaccine delivery systems for cancer therapy","volume":"10","author":"Bolhassani","year":"2011","journal-title":"Mol Cancer"},{"issue":"February (8)","key":"10.1016\/j.vaccine.2012.11.068_bib0675","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.vaccine.2005.09.009","article-title":"Systemic immune responses in sheep, induced by a novel nano-bead adjuvant","volume":"24","author":"Scheerlinck","year":"2006","journal-title":"Vaccine"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0680","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.4049\/jimmunol.173.5.3148","article-title":"Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors","volume":"173","author":"Fifis","year":"2004","journal-title":"J Immunol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0685","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1172\/JCI39293","article-title":"Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice","volume":"120","author":"Zhu","year":"2010","journal-title":"J Clin Invest"},{"issue":"February (7335)","key":"10.1016\/j.vaccine.2012.11.068_bib0690","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"issue":"February (9\/10)","key":"10.1016\/j.vaccine.2012.11.068_bib0695","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0264-410X(02)00536-4","article-title":"Liposomal delivery of antigen to human dendritic cells","volume":"21","author":"Copland","year":"2003","journal-title":"Vaccine"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2012.11.068_bib0700","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0968-0896(02)00644-2","article-title":"Protection against Leishmania major infection by oligomannose-coated liposomes","volume":"11","author":"Shimizu","year":"2003","journal-title":"Bioorg Med Chem"},{"issue":"December (4)","key":"10.1016\/j.vaccine.2012.11.068_bib0705","first-page":"255","article-title":"Leishmania donovani-derived lipophosphoglycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamsters (Mesocricetus auratus) and BALB\/c mice against Leishmania donovani","volume":"70","author":"Tonui","year":"2003","journal-title":"Onderstepoort J Vet Res"},{"issue":"March\u2013April (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0710","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0769-2625(88)90036-0","article-title":"Vaccination of mice against Leishmania mexicana amazonensis with microsomal fraction associated with BCG","volume":"139","author":"Goncalves da Costa","year":"1988","journal-title":"Ann Inst Pasteur Immunol"},{"issue":"March (Pt 3)","key":"10.1016\/j.vaccine.2012.11.068_bib0715","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182097002175","article-title":"Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG","volume":"116","author":"Dube","year":"1998","journal-title":"Parasitology"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2012.11.068_bib0720","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/pmic.200800533","article-title":"Mining the Leishmania genome for novel antigens and vaccine candidates","volume":"9","author":"Herrera-Najera","year":"2009","journal-title":"Proteomics"},{"issue":"November (31\/32)","key":"10.1016\/j.vaccine.2012.11.068_bib0725","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1016\/S0264-410X(02)00354-7","article-title":"Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine","volume":"20","author":"Serezani","year":"2002","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0730","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.exppara.2008.09.019","article-title":"Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis","volume":"121","author":"Bhardwaj","year":"2009","journal-title":"Exp Parasitol"},{"issue":"November (9)","key":"10.1016\/j.vaccine.2012.11.068_bib0735","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.4049\/jimmunol.139.9.3118","article-title":"Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract","volume":"139","author":"Scott","year":"1987","journal-title":"J Immunol"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0740","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4049\/jimmunol.139.1.221","article-title":"Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes","volume":"139","author":"Scott","year":"1987","journal-title":"J Immunol"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2012.11.068_bib0745","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1128\/IAI.58.7.2198-2203.1990","article-title":"Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses","volume":"58","author":"Nascimento","year":"1990","journal-title":"Infect Immun"},{"issue":"October (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0750","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.femsim.2004.05.008","article-title":"Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection","volume":"42","author":"Tewary","year":"2004","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2012.11.068_bib0755","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1016\/j.vaccine.2006.01.030","article-title":"Comparison of potential protection induced by three vaccination strategies (DNA\/DNA, Protein\/Protein and DNA\/Protein) against Leishmania major infection using signal peptidase type I in BALB\/c mice","volume":"24","author":"Rafati","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.11.068_bib0760","doi-asserted-by":"crossref","first-page":"e14644","DOI":"10.1371\/journal.pone.0014644","article-title":"Efficacy and durability of DNA\/DNA, DNA\/protein and protein\/protein based vaccination using gp63 against Leishmania donovani in BALB\/c mice","volume":"6","author":"Mazumder","year":"2011","journal-title":"PLoS ONE"},{"issue":"April (15)","key":"10.1016\/j.vaccine.2012.11.068_bib0765","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1016\/j.vaccine.2005.11.067","article-title":"Potential of KM+ lectin in immunization against Leishmania amazonensis infection","volume":"24","author":"Teixeira","year":"2006","journal-title":"Vaccine"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2012.11.068_bib0770","first-page":"623","article-title":"Current status and perspectives of the immunotherapy of leishmaniasis","volume":"11","author":"El-On","year":"2009","journal-title":"Isr Med Assoc J"},{"issue":"July (27\/28)","key":"10.1016\/j.vaccine.2012.11.068_bib0775","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1016\/j.vaccine.2006.03.023","article-title":"Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis","volume":"24","author":"Calvopina","year":"2006","journal-title":"Vaccine"},{"issue":"May (23)","key":"10.1016\/j.vaccine.2012.11.068_bib0780","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1016\/j.vaccine.2010.01.015","article-title":"Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis","volume":"28","author":"Nagill","year":"2010","journal-title":"Vaccine"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2012.11.068_bib0785","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1128\/IAI.71.6.3172-3182.2003","article-title":"Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection","volume":"71","author":"Colmenares","year":"2003","journal-title":"Infect Immun"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0790","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/eji.200737660","article-title":"Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania","volume":"38","author":"Dondji","year":"2008","journal-title":"Eur J Immunol"},{"issue":"March (14)","key":"10.1016\/j.vaccine.2012.11.068_bib0795","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1016\/j.vaccine.2005.12.039","article-title":"Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum","volume":"24","author":"Poot","year":"2006","journal-title":"Vaccine"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2012.11.068_bib0800","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.imbio.2012.02.008","article-title":"115kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-gamma induced down-regulation of TNF-alpha mediated MMP-9 activity","volume":"218","author":"Choudhury","year":"2013","journal-title":"Immunobiology"},{"issue":"January (8)","key":"10.1016\/j.vaccine.2012.11.068_bib0805","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.vaccine.2004.08.022","article-title":"Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis","volume":"23","author":"Silva","year":"2005","journal-title":"Vaccine"},{"issue":"November (12\/13)","key":"10.1016\/j.vaccine.2012.11.068_bib0810","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.micinf.2010.06.008","article-title":"Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB\/c mice against Leishmania chagasi and Leishmania amazonensis challenge","volume":"12","author":"Chavez-Fumagalli","year":"2010","journal-title":"Microbes Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2012.11.068_bib0815","doi-asserted-by":"crossref","first-page":"e5820","DOI":"10.1371\/journal.pone.0005820","article-title":"Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis","volume":"4","author":"Bhowmick","year":"2009","journal-title":"PLoS ONE"},{"issue":"January (8)","key":"10.1016\/j.vaccine.2012.11.068_bib0820","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.vaccine.2004.07.044","article-title":"Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana","volume":"23","author":"Saravia","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.11.068_bib0825","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/bmb\/62.1.29","article-title":"Delivery technologies for human vaccines","volume":"62","author":"Moingeon","year":"2002","journal-title":"Br Med Bull"},{"issue":"August (Suppl. 3)","key":"10.1016\/j.vaccine.2012.11.068_bib0830","doi-asserted-by":"crossref","first-page":"C25","DOI":"10.1016\/j.vaccine.2010.07.021","article-title":"Unmet needs in modern vaccinology: adjuvants to improve the immune response","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0835","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1006\/viro.1999.9765","article-title":"Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS)","volume":"259","author":"Ennis","year":"1999","journal-title":"Virology"},{"issue":"December (9\/10)","key":"10.1016\/j.vaccine.2012.11.068_bib0840","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0264-410X(00)00310-8","article-title":"A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines","volume":"19","author":"Rimmelzwaan","year":"2000","journal-title":"Vaccine"},{"issue":"November (2)","key":"10.1016\/j.vaccine.2012.11.068_bib0845","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vaccine.2004.05.013","article-title":"Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia","volume":"23","author":"Frazer","year":"2004","journal-title":"Vaccine"},{"issue":"June (11\/12)","key":"10.1016\/j.vaccine.2012.11.068_bib0850","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.drudis.2009.02.009","article-title":"The path to a successful vaccine adjuvant \u2013 \u2018the long and winding road\u2019","volume":"14","author":"O\u2018Hagan","year":"2009","journal-title":"Drug Discov Today"},{"issue":"September (27\/28)","key":"10.1016\/j.vaccine.2012.11.068_bib0855","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.vaccine.2004.03.032","article-title":"Aluminium adjuvants \u2013 in retrospect and prospect","volume":"22","author":"Lindblad","year":"2004","journal-title":"Vaccine"},{"issue":"November ((6)","key":"10.1016\/j.vaccine.2012.11.068_bib0860","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/CDLI.7.6.899-903.2000","article-title":"Calcium phosphate nanoparticle adjuvant","volume":"7","author":"He","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.11.068_bib0865","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nbt0397-221","article-title":"High-tech herbal medicine: plant-based vaccines","volume":"15","author":"Arntzen","year":"1997","journal-title":"Nat Biotechnol"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2012.11.068_bib0870","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1586\/14760584.7.8.1141","article-title":"Epaxal: a virosomal vaccine to prevent hepatitis A infection","volume":"7","author":"Bovier","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"44\u201346","key":"10.1016\/j.vaccine.2012.11.068_bib0875","doi-asserted-by":"crossref","first-page":"6632","DOI":"10.1016\/j.vaccine.2006.05.084","article-title":"Inflexal\u00ae V \u2013 the influenza vaccine with the lowest ovalbumin content","volume":"24","author":"K\u00fcrsteiner","year":"2006","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12017185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12017185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T12:11:09Z","timestamp":1687867869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12017185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":175,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0264410X12017185"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.11.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}